A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

  title={A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls},
  author={Donald C. Goff and Lisa Sullivan and Joseph P. McEvoy and Jonathan M. Meyer and Henry A. Nasrallah and Gail L Daumit and Steven Lamberti and Ralph B. D'Agostino and T. Scott Stroup and Sonia M. Davis and Jeffrey A. Lieberman},
  journal={Schizophrenia Research},

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia

Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit

Patients of schizophrenia have a high prevalence of MS and CVR factors and there is a need to screen the patient of schizophrenia for the same and manage the same as early as possible during the course of illness.

Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study

CHD is prevalent in patients with schizophrenia in Lebanon and Physicians are recommended to monitor the components of the metabolic syndrome to identify patients with increased risk of cardiovascular diseases.

The Relationship between 10 Years Risk of Cardiovascular Disease and Schizophrenia Symptoms: Preliminary Results

A relationship between the risk of cardiovascular disease and the duration and overall severity of schizophrenia is suggested and the role of antipsychotics in this relationship is highlighted.

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey

In countries where the general population prevalence of MS is already too high, schizophrenia patients younger than 30 years of age might be under higher risk of morbidity and mortality related with MS.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

The risk of CVD mortality in schizophrenia does not differ between clozapine and risperidone in adults despite known differences in risk profiles for weight gain and metabolic side effects, however, one cannot rule out an increased risk ofCVD mortality among those starting treatment at ages 55 years or older.

Assessment of risk for cardiovascular disease in a sample of schizophrenic patients

The study points to the measurement of CRP and screening of lipid levels as an improved method for identifying schizophrenic patients at risk for cardiovascular events.

Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics

Patients with schizophrenia showed a high prevalence of metabolic syndrome, but most of them had low risk of developing cardiovascular disease, and regular screening and early interventions to modify the risk factors of metabolic Syndrome are suggested.



Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome

These long-term patients with chronic schizophrenia or schizoaffective disorder have increased CHD risks best captured by the metabolic syndrome conceptualization coupled with a high rate of cigarette smoking, consistent with increased cardiovascular morbidity and decreased life expectancy in both men and women.

Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia

Among patients with schizophrenia, cardiovascular risk was inversely associated with intensity of use of antipsychotic drugs, suggesting that the observed risks may not be due to a simple or direct effect of drugs.

The association between schizophrenia and cancer: a population-based mortality study

Prevalence and correlates of diabetes in national schizophrenia samples.

This study of diabetes in the early 1990s suggests that even before the widespread use of the atypical antipsychotic drugs, diabetes was a major problem for persons with schizophrenia.

Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.

Interventions that have reduced medical morbidity in the general population can be adopted to reduce premature mortality in individuals with schizophrenia.

Causes of the excess mortality of schizophrenia.

Some of the excess mortality of schizophrenia could be lessened by reducing patients' smoking and exposure to other environmental risk factors and by improving the management of medical disease, mood disturbance and psychosis.

Quality of medical care and excess mortality in older patients with mental disorders.

Deficits in quality of medical care seemed to explain a substantial portion of the excess mortality experienced by patients with mental disorders after myocardial infarction, and the potential importance of improving patients' medical care as a step toward reducing their excess mortality is suggested.

Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study

Assessment of mortality over time after a first admission to hospital with schizophrenia in Stockholm County found that over expected numbers of deaths and relative risks (95% confidence intervals) for different causes of death are similar.

The unhealthy lifestyle of people with schizophrenia

People with schizophrenia have an unhealthy lifestyle, which probably contributes to the excess mortality of the disease, and are therefore an appropriate target group for health promotion interventions.

Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study

The lifestyle of people with schizophrenia must give cause for concern in relation to CHD Care from secondary care services must address physical as well as mental health.